Retatrutide vs Tesamorelin
Retatrutide is an investigational single-peptide triple agonist of the GIP, GLP-1 and glucagon receptors, studied in phase 2 trials in obesity, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, with a phase 3 programme under way. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone that stimulates endogenous pulsatile growth hormone secretion, approved for HIV-associated lipodystrophy on the basis of large phase 3 trials with visceral adipose tissue as the primary endpoint. They appear together in discussions of body-fat reduction, but they act through unrelated hormonal systems and were developed for different populations. No study has tested them against each other or in combination. Their trial programmes measured different primary endpoints in different patient groups, so the two sets of results cannot be placed on a common scale.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published trial has compared retatrutide with tesamorelin, whether as parallel arms, as an active comparator or as a combination. Searches of PubMed and Europe PMC returned no head-to-head study; the records naming both are review articles on therapeutic peptides in metabolic and endocrine conditions, a review of thermogenesis-stimulating agents, and a paediatric obesity practice statement, none of which generate comparative data. Retatrutide's phase 2 programme used placebo comparators and, in the type 2 diabetes trial, dulaglutide as an active comparator, while tesamorelin's phase 3 programme used placebo in people with HIV and abdominal fat accumulation. Any comparison is therefore indirect, drawn from trials with different primary endpoints, different populations and different durations, which limits what can be concluded about their relative effects.
Side by side.
| Retatrutide | Tesamorelin | |
|---|---|---|
| Evidence maturity | Clinical | Approved drug |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 13 | 11 |
| Newest paper | 2026 | 2026 |
| Mechanism | Single peptide acting as an agonist at three incretin and glucagon-family receptors simultaneously: GIP, GLP-1 and glucagon. | GHRH receptor agonist that stimulates endogenous, pulsatile growth hormone secretion from the pituitary rather than acting on adipose tissue directly. |
| Regulatory status | Investigational and unapproved in every jurisdiction as of August 2026, with a registrational phase 3 programme in progress. | Approved for HIV-associated lipodystrophy. Its evidence base is anchored by a completed regulatory programme in that indication. |
| Population studied | Adults with obesity, with type 2 diabetes, and with metabolic dysfunction-associated steatotic liver disease, in trials of 72 to 537 participants, with a phase 3 basket programme of more than 5,800 planned participants across obesity, obstructive sleep apnoea and knee osteoarthritis. | Predominantly people with HIV and excess abdominal fat, in multicentre trials of which the largest randomised 412 patients over 26 weeks. Later investigator-initiated work extended to hepatic fat, cognition and physical function. |
| Primary endpoint of the pivotal work | Body weight change in obesity and HbA1c in type 2 diabetes, with liver fat content in the MASLD sub-study. | Visceral adipose tissue, measured by imaging, in the phase 3 HIV lipodystrophy trials. |
| What is reported outside the primary indication | Post-hoc and substudy analyses of kidney parameters, body composition, appetite and eating behaviour, cardiovascular risk biomarkers, blood pressure and lipids, all derived from the phase 2 trials. | Randomised trials in NAFLD in people with HIV, in cognition in mild cognitive impairment, and in neurocognitive impairment in people with HIV. The largest recent HIV neurocognitive trial found no significant between-group difference. |
| Documented tolerability signal | Predominantly gastrointestinal adverse events, reported alongside the dose-dependent efficacy findings in the phase 2 trials. | Reported safety considerations centre on glucose homeostasis, arthralgia and IGF-1 elevation, consistent with GH-axis stimulation. |
| Principal published gap | Long-term safety, cardiovascular outcome data and durability of effect after discontinuation are not established in peer-reviewed reports. The TRIUMPH phase 3 obesity, sleep apnoea and osteoarthritis trials had published only rationale and design papers as of August 2026, with efficacy disclosed as sponsor topline announcements. | Controlled evidence outside HIV-associated visceral adiposity and hepatic steatosis remains limited. No histology-based MASLD endpoints and no long-term cardiovascular or oncological outcome data have been established, and results from the TRIUMPH exercise protocol in HIV have not been reported. |
And what it does not.
These compounds were developed to solve different problems, and their trial programmes reflect that, which is why no comparison exists and why constructing one from the separate results would be misleading. Retatrutide has produced dose-dependent reductions in body weight, HbA1c and liver fat in randomised phase 2 trials and now has a first phase 3 readout in type 2 diabetes, but it remains investigational, with long-term safety, cardiovascular outcomes and durability after discontinuation unpublished, and with most phase 3 obesity results still outside the peer-reviewed record. Tesamorelin has a completed regulatory programme, but that programme addressed visceral adipose tissue in people with HIV and abdominal fat accumulation, and its evidence beyond that population and hepatic steatosis is limited and, in the neurocognitive setting, inconsistent. Nothing in either literature supports a statement about which reduces body fat more, because the trials measured different things in different people over different periods and no shared control links them.
Common questions.
- Do these two compounds act on the same hormonal system?
No. Retatrutide is a single peptide agonist at the GIP, GLP-1 and glucagon receptors, systems associated with appetite, glycaemic control and energy expenditure. Tesamorelin acts at the GHRH receptor to stimulate endogenous pulsatile growth hormone secretion. The two engage separate axes, and no published work has examined what happens when both are engaged in the same person.
- What did tesamorelin's pivotal trials use as their primary endpoint?
Visceral adipose tissue measured by imaging, in people with HIV and abdominal fat accumulation. The largest of these randomised 412 patients over 26 weeks. That endpoint is a specific fat compartment in a specific population rather than total body weight in a general population, which is why the results are not directly comparable with weight-loss trial figures.
- How far has the retatrutide phase 3 programme been published?
As of August 2026 the first phase 3 readout in the peer-reviewed literature was TRANSCEND-T2D-1, a double-blind randomised trial in 537 adults with type 2 diabetes over 40 weeks. The TRIUMPH-1 to TRIUMPH-4 trials in obesity, obstructive sleep apnoea and knee osteoarthritis had published rationale and design papers only, with efficacy results disclosed by the sponsor as topline announcements rather than peer-reviewed reports.
- Has either compound been studied for liver fat?
Both have, in separate trials. Retatrutide was tested in a phase 2a randomised, double-blind, placebo-controlled sub-study of 98 adults with metabolic dysfunction-associated steatotic liver disease over 48 weeks, which reported dose-dependent reductions in liver fat content. Tesamorelin was tested in a randomised, double-blind, multicentre trial of 61 people with HIV and NAFLD over 12 months. Neither programme has established histology-based endpoints, and the two populations differ substantially.
- What has the research on tesamorelin and cognition reported?
Results have been small and inconsistent. A randomised double-blind placebo-controlled trial with 137 completers, 66 of whom had mild cognitive impairment, examined cognitive function over 20 weeks, and a 2026 randomised study of 22 adults examined cognition and brain connectivity over 10 weeks. A phase 2 multicentre randomised trial in 73 persons with HIV and abdominal obesity found no significant between-group difference on neurocognitive impairment.
- Why is body-composition data reported for both but still not comparable?
Because it was collected under different conditions. Retatrutide body-composition data come from a substudy of 189 adults with type 2 diabetes over 36 weeks within its phase 2 programme. Tesamorelin body-composition data come from HIV lipodystrophy trials pooled in meta-analyses, where the framing question was visceral fat reduction and lean mass preservation in that population. Different populations, durations and comparators mean the numbers do not sit on a common scale.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.